(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 3.98% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.88%.
Myriad Genetics's revenue in 2025 is $832,900,000.On average, 16 Wall Street analysts forecast MYGN's revenue for 2025 to be $77,979,771,442, with the lowest MYGN revenue forecast at $73,860,685,805, and the highest MYGN revenue forecast at $80,739,475,079. On average, 16 Wall Street analysts forecast MYGN's revenue for 2026 to be $82,407,765,241, with the lowest MYGN revenue forecast at $74,995,830,255, and the highest MYGN revenue forecast at $86,960,438,840.
In 2027, MYGN is forecast to generate $87,179,093,714 in revenue, with the lowest revenue forecast at $77,149,813,370 and the highest revenue forecast at $94,812,474,913.